射频消融治疗局部复发甲状腺乳头状癌的较长期结局
该回顾性研究纳入29例患者共46个局部复发甲状腺乳头状癌病灶,于2008年9月至2012年4月接受超声引导下射频消融并随访至少5年。平均随访80±17.3个月,肿瘤体积从消融前0.25±0.42 mL降至最终评估时0.01±0.08 mL(p<0.001),平均体积缩小99.5%±2.9%,46个肿瘤中42个(91.3%)完全消失,血清甲状腺球蛋白从2.55±4.7降至0.75±1.83 ng/dL(p<0.001),随访期间无延迟并发症。作者结论认为射频消融似乎是治疗局部复发甲状腺乳头状癌有效的微创方法,即使在较长期亦如此。
要点
- 46个复发灶中42个(91.3%)最终完全消失,平均体积缩小99.5%±2.9%。
- 肿瘤体积由0.25±0.42 mL降至0.01±0.08 mL,血清甲状腺球蛋白由2.55±4.7降至0.75±1.83 ng/dL。
- 平均随访80±17.3个月期间无与射频消融相关的延迟并发症。
核心结论
- 射频消融似乎是对局部复发甲状腺乳头状癌有效的微创治疗,即使在较长期随访中亦如此。
研究设计与样本
- 回顾性研究,纳入29例患者共46个局部复发甲状腺乳头状癌病灶,2008年9月至2012年4月接受超声引导下射频消融,随后随访至少5年。
关键影像表现/征象
- 超声随访显示肿瘤体积从消融前0.25±0.42 mL降至最终评估时0.01±0.08 mL(p<0.001)。
- 平均体积缩小99.5%±2.9%,46个治疗肿瘤中42个(91.3%)在最终评估时完全消失。
诊断标准与关键数值
- 随访包括术后1、3、6、12个月及此后每6–12个月复查超声大小变化和甲状腺球蛋白水平。
- 平均血清甲状腺球蛋白从2.55±4.7降至0.75±1.83 ng/dL(p<0.001),生化缓解率为51.7%。
临床应用与阅片要点
- 作者结论认为射频消融似乎是局部复发甲状腺乳头状癌有效的局部控制治疗选择,较长期平均体积缩小99.5%且91.3%治疗肿瘤完全消失。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The purpose of this study was to evaluate the longer-term efficacy of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC).
METHODS: We retrospectively reviewed 29 patients who underwent RFA for 46 recurrent PTC between September 2008 and April 2012 and were subsequently followed up for at least 5 years. Follow-up included size change on US and thyroglobulin (Tg) level at 1, 3, 6, and 12 months and every 6-12 months thereafter. Any complications were reported during follow-up.
RESULTS: The mean follow-up duration after RFA was 80 ± 17.3 months (range, 60-114 months). Tumor volume decreased significantly, from 0.25 ± 0.42 mL before ablation to 0.01 ± 0.08 mL at the final evaluation (p < 0.001), with a mean volume reduction of 99.5% ± 2.9%. Forty-two of the 46 treated tumors (91.3%) had completely disappeared by the final evaluation. The mean serum Tg level decreased from 2.55 ± 4.7 to 0.75 ± 1.83 ng/dL (p < 0.001). There were no delayed complications associated with RFA during the follow-up period.
CONCLUSIONS: RFA seems to be an effective minimally invasive therapy for the treatment of locally recurrent PTC even in the longer-term period.
KEY POINTS: • RFA is an effective local control treatment option for recurrent PTCs even in the longer-term period with mean tumor VRR of 99.5% and the complete disappearance of the treated tumors in 91.3%. • The mean serum Tg level decreased significantly after RFA and biochemical remission rate was 51.7%. • No delayed complication after RFA for local recurrent PTC.
引用
- Chung SR, Baek JH, Choi YJ, et al. Longer-term outcomes of radiofrequency ablation for locally recurrent papillary thyroid cancer. Eur Radiol. 2019. PMID: 30805701. doi:10.1007/s00330-019-06063-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。